Brought to you by 
Adlai Nortye gets Reolysin rights from Oncolytics Biotech
15 Jul 2019
Executive Summary
Oncolytics Biotech Inc. granted Adlai Nortye exclusive rights to develop and sell its cancer therapy Reolysin (pelareorep) in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adlai Nortye gets Reolysin rights from Oncolytics Biotech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice